Document Detail


The absorption profile of pregabalin in chronic pancreatitis.
MedLine Citation:
PMID:  22716224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It was recently shown that pregabalin decreased pain associated with chronic pancreatitis. It is well known that pancreatitis patients suffer from fat malabsorption with accompanying diarrhoea because of loss of exocrine pancreatic enzyme production. This may lead to changes in the mucosal surface in the small intestine and possibly affect the absorption of pregabalin. The pharmacokinetics of pregabalin has never been investigated in patients suffering from chronic pancreatitis. The aim of this study was to develop a population pharmacokinetic model of pregabalin administered to patients with chronic pancreatitis. The pregabalin population pharmacokinetic analysis was conducted on data from fifteen patients with chronic pancreatitis. Each patient received 75 mg of pregabalin (oral capsule). Pregabalin concentrations were measured using a validated liquid chromatographic method. Data analysis was performed using non-linear mixed effects modelling methodology as implemented by NONMEM. A one-compartment model with first-order absorption and elimination adequately described pregabalin pharmacokinetics. Time to maximum observed plasma concentration (T(max) ) was 1.53 (95% CI 1.09-2.05). The maximum plasma concentration (C(max) ) was 1.98 μg/ml (95% CI 1.69-2.34), and area under the plasma concentration-time profile (area under the curve) was 18.2 μg*hr/ml (95% CI 14.7-26.3). Pregabalin is well absorbed in patients with chronic pancreatitis, and the pharmacokinetic profile of pregabalin is not extensively affected by chronic pancreatitis.
Authors:
Anne E Olesen; Erik Olofsen; Søren S Olesen; Camilla Staahl; Trine Andresen; Albert Dahan; Asbjørn M Drewes
Related Documents :
6662754 - The syed-neblett interstitial template in locally advanced gynecological malignancies.
21944474 - Gait pattern classification in children with charcot-marie-tooth disease type 1a.
21988704 - The added value of quantitative analysis of on-therapy impedance-ph parameters in disti...
902244 - Transthoracic needle biopsy of mediastinal and hilar lesions.
24215034 - How i treat unexplained refractory iron deficiency anemia.
1985354 - Coronary angioplasty of diffuse coronary artery disease.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-07-11
Journal Detail:
Title:  Basic & clinical pharmacology & toxicology     Volume:  111     ISSN:  1742-7843     ISO Abbreviation:  Basic Clin. Pharmacol. Toxicol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-19     Completed Date:  2013-04-25     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  101208422     Medline TA:  Basic Clin Pharmacol Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  385-90     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.
Affiliation:
Mech-Sense, Department of Gastroenterology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorption
Adolescent
Adult
Aged
Dose-Response Relationship, Drug
Female
Half-Life
Humans
Male
Middle Aged
Models, Biological
Netherlands
Pancreatitis, Chronic / drug therapy*,  physiopathology
Young Adult
gamma-Aminobutyric Acid / analogs & derivatives*,  pharmacokinetics
Chemical
Reg. No./Substance:
55JG375S6M/pregabalin; 56-12-2/gamma-Aminobutyric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans.
Next Document:  Puberty as a life history transition.